

CHARTER SCIENCE AND TECHNOLOGY COMMITTEE

Status

The Science and Technology Committee (the “**Committee**”) is a committee of the Board of Directors (the “**Board**”) of Virpax Pharmaceuticals, Inc. (the “**Company**”).

Membership

1. The Committee shall consist of two (2) or more Directors. At least one (1) member of the Committee shall, in the judgment of the Board, have scientific research expertise. The Committee may engage external consultants, providing a broad range of expertise in both basic and clinical sciences, as well as technologies.
2. The Chair of the Committee shall be designated by the Board, provided that if the Board does not designate a Chair, the members of the Committee, by a majority vote, may designate a Chair.
3. The members of the Committee shall be elected by the Board. Each member of the Committee shall serve for such term or terms as the Board may determine or until his or her earlier resignation, removal or death. Any vacancy on the Committee shall be filled by the Board. No member of the Committee shall be removed as a member except by the Board.

Purpose

The Committee shall periodically examine management’s strategic direction and investment in the Company’s biopharmaceutical research and development and technology initiatives. The Committee will function as a broadly knowledgeable and objective group of scientists and non-scientists to consider and report periodically to the Board on matters relating to the investment in the Company’s research and development and technology initiatives.

Responsibilities

The following responsibilities are within the authority of the Committee and shall include, consistent with and subject to applicable law and rules and regulations promulgated by the Food and Drug Administration (“**FDA**”) or any other applicable regulatory authority:

1. Review, evaluate and report to the Board regarding the performance of the research and development leaders in achieving long-term strategic goals and objectives and the quality and direction of the Company’s biopharmaceutical research and development programs.
2. Identify and discuss significant emerging science and technology issues and trends.
3. Determine whether there is sufficient and ongoing external review from world-class experts across both research and development, pertaining to the Company’s therapeutic

areas.

4. Evaluate the soundness/risks associated with the technologies in which the Company is investing its research and development efforts.
5. Periodically review the Company's overall patent strategies.

Meetings

1. The Committee shall meet at such times as it deems to be necessary or appropriate, but not less than twice each year, and shall report at the next Board meeting following each Committee meeting.
2. The Committee may meet privately with independent consultants and be free to speak directly and independently with any members of management in discharging its responsibilities.
3. The Committee shall maintain minutes of its meeting and records relating to those meetings.

Adopted by the Board: November 18, 2020